• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

WHO Issues First List Of Potential Deadly Bacteria If No New Antibiotics Are Found

27/02/2017 by Catherine Saez, Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Microbial resistance to antibiotics has been rising and the world is now facing the serious possibility of falling back to the days when infectious diseases were hardly treatable. The World Health Organization today published a list of bacteria for which new antibiotics are most urgently needed, to help with the race against time, as the medical world is running out of treatment options.

The list of antibiotic-resistant ‘priority pathogens’ is the first published by the WHO, according to a press release. The list was drawn up “in a bid to guide and promote research and development (R&D) of new antibiotics, as part of WHO’s efforts to address growing global resistance to antimicrobial medicines.”

Bacteria have gotten smarter over time as they were countered by antibiotics and developed ways to survive. The list highlights the thread of gram-negatives bacteria which have become resistant to multiple antibiotics.

The list is organised into three categories according to the urgency of the need for new antibiotics: critical, high, and medium.

The need for new antibiotics is expected to be discussed by health experts from G20 countries this week in Berlin, according to the release.

The list, according to WHO, is “intended to spur governments to put in place policies that incentivize basic science and advanced R&D by both publicly funded agencies and the private sector investing in new antibiotic discovery. It will provide guidance to new R&D initiatives such as the WHO/DNDi Global Antibiotic R&D Partnership that is engaging in not-for-profit development of new antibiotics.” DNDi is the Drugs for Neglected Disease initiative.

The release specifies that tuberculosis has not been included in the list because it is targeted by other programmes. Streptococcus A and B and chlamydia, which have low levels of resistance to existing treatments were not included either.

WHO priority pathogens list for R&D of new antibiotics

“Priority 1: Critical

  1. Acinetobacter baumannii, carbapenem-resistant
  2. Pseudomonas aeruginosa, carbapenem-resistant
  3. Enterobacteriaceae, carbapenem-resistant, ESBL-producing

Priority 2: high

4.Enterococcus faecium, vancomycin-resistant

5.Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant

6.Helicobacter pylori, clarithromycin-resistant

7.Campylobacter spp., fluoroquinolone-resistant

8.Salmonellae, fluoroquinolone-resistant

9.Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant

Priority 3: MEDIUM

10.Streptococcus pneumoniae, penicillin-non-susceptible

11.Haemophilus influenzae, ampicillin-resistant

12.Shigella spp., fluoroquinolone-resistant”

Reactions

Médecins Sans Frontières (MSF, Doctors Without Borders) issued an immediate reaction to the announcement, calling it a “valuable and urgently needed tool.”

“It’s getting harder to treat people for drug-resistant infections in the resource-limited settings in which we work. With the priority pathogen list, we need to urgently see new antibiotics developed that are affordable, appropriate, and accessible fill a depleted drug pipeline,” Rupa Kanapathipillai, MSF antimicrobial resistance advisor.

“It’s important to remember that tackling the growing AMR crisis isn’t just about new drugs. Improved diagnostics – ones that are fast, easy to use in field settings, and that can determine what infections are bacterial, identify what bacteria they are, and assess whether they are resistant to certain drugs – are crucial to reducing inappropriate antibiotic use in the first place,” Kanapathipillai said. “Governments have made important commitments to change how R&D investment into new antibiotics is spent; they should address priority health needs, and new antibiotics developed with public money should be affordable, and appropriately made available to everybody who needs them, no matter where they live.”

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"WHO Issues First List Of Potential Deadly Bacteria If No New Antibiotics Are Found" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, English, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, WHO

Trackbacks

  1. Links 28/2/2017: Wine 1.8.7, AWS Goes Belly-up | Techrights says:
    28/02/2017 at 11:53 pm

    […] WHO Issues First List Of Potential Deadly Bacteria If No New Antibiotics Are Found […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.